Outcomes of Kidney Transplantation in Scleroderma Patients: A U.S. National Database Study
Clinical Kidney Journal · 11.11.2026
DOI: 10.1093/ckj/sfag400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 11.11.2026. Verfasst von Shengliang He und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Scleroderma is a systemic autoimmune disease that can progress to end-stage renal disease. Historically, kidney transplantation in scleroderma patients was associated with poor outcomes, but contemporary results in the United States remain understudied.
Methods
Adult kidney transplant recipients with scleroderma (1990-2020) were identified from the SRTR database. Control groups included patients with diabetes mellitus, IgA nephropathy, and all non-scleroderma recipients. Kaplan-Meier methods were used to estimate patient survival and graft survival.
Results
Among 347,598 kidney transplant recipients, 399 had scleroderma. Compared with non-scleroderma recipients, those with scleroderma were more likely to receive a living donor transplant (45.1% vs. 34.3%, p<0.001), be female (77.9% vs. 39.3%, p<0.001), be white (86.5% vs. 66.8%, p<0.001), and have a lower body mass index (22.9 vs. 27.1 kg/m², p<0.001). After adjustment for various factors, scleroderma was associated with higher mortality compared with non-scleroderma recipients (HR 1.39, 95% CI 1.19–1.65) and recipients with IgA nephropathy (HR 2.98, 95% CI 2.48–3.58), but comparable to recipients with diabetes mellitus (HR 0.88, 95% CI 0.75–1.04). Death-censored graft survival was comparable between recipients with scleroderma and those with diabetes mellitus (HR 0.91, 95% CI 0.69–1.19) or non-scleroderma recipients (HR 1.27, 95% CI 0.97–1.67), but was inferior compared with recipients with IgA nephropathy (HR 2.11, 95% CI 1.59–2.80).
Conclusion
Outcomes of kidney transplantation in scleroderma patients are similar to patients with diabetes but inferior to patients with IgA nephropathy and kidney transplant is a viable option for scleroderma patients with end stage kidney disease.
Zitieren
APA
He, S., Yasmin, F., Wilson, F., Kuppachi, S., & Kumar, A. (2026). Outcomes of Kidney Transplantation in Scleroderma Patients: A U.S. National Database Study. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfag400
Vancouver
He S, Yasmin F, Wilson F, Kuppachi S, Kumar A. Outcomes of Kidney Transplantation in Scleroderma Patients: A U.S. National Database Study. Clinical Kidney Journal. 2026. doi:10.1093/ckj/sfag400
BibTeX
@article{He2026,
author = {He, Shengliang and Yasmin, Farah and Wilson, Francis and Kuppachi, Sarat and Kumar, Abhishek},
title = {Outcomes of Kidney Transplantation in Scleroderma Patients: A U.S. National Database Study},
journal = {Clinical Kidney Journal},
year = {2026},
doi = {10.1093/ckj/sfag400}
}
EUVIMED